AKT1 and liver cancer: In support of our observations, studies have shown that PIK3CA is mutated in up to 30% of CRC as well as other tumors such as breast, ovarian, and liver cancer [47] typically leading to activation of the PI3K/AKT/mTOR signaling pathway.